Table 2.
Patients characteristics among the 35 studies included in this review.
| References | Cancer type | Cancer stage | Metastasis | Treatment | Time since diagnosis | Age at diagnosis | Age | Sex |
|---|---|---|---|---|---|---|---|---|
| Andrykowski et al. (18) | Breast | 0-IIIA | Not specified | Adjuvant therapy: chemotherapy or radiotherapy; Breast surgery: lumpectomy or astectomy | Not specified | Mean: 54.7 ± 10.6 | Not specified | All female |
| Anota et al. (19) | Breast | Not specified | 301 patients had a lymph node dissection | Chemotherapy; hormone therapy; radiotherapy; surgery (mastectomy) | Diagnosed between February 2006 and February 2008 | Not specified | Mean: 58.4 ± 11 | All female |
| Bernhard et al. (20) | Colon | pT1-4 pN>0 M0 and pT3-4 pN0 M0 | Not specified | Chemotherapy; surgery | Not specified | Not specified | Median: 62 Range: 27–88 | 59% male |
| Brinksma et al. (21) | Hematologic; brain tumor; solid tumor | Not specified | Not specified | Not specified | Not specified | Not specified | Child report Mean: 14 Range: 8–17 Parent report Mean: 9 Range: 2–17 | Child report: 54% female; Parent report: 55% female |
| Broberger et al. (22) | Lung | Not specified | Not specified | Not specified | 3-month follow-up: 119 days 6-month follow-up: 219 days | Not specified | Mean: 64 ± 10 Range: 47–95 | 49% female |
| Dabakuyo et al. (23) | Breast | AJCC stage: 0–4 | 163 patients had a lymph node biopsy | Chemotherapy; hormone therapy; radiotherapy; surgery (mastectomy) | Not specified | Divided into two groups: <65 (younger); >65 (older) | Mean: 58.4 ± 11 | All female |
| Echteld et al. (24) | Lung; colorectal: urogenital; breast; melanoma; sarcoma; other | Not specified | Not specified | Not specified | Not specified | Not specified | Mean: 55.3 Range: 27–80 | 69% female |
| Gerlich et al. (25) | Prostate | TNM classification: T1–T4 | Not specified | Radiotherapy; surgery | Not specified | Not specified | Mean: 64.7 ± 7.1 | All male |
| Hagedoorn et al. (26) | Breast; gastrointestinal tumors; lymphomas; genitourinary; lung; gynecological | Not specified | Yes, in 140 patients | Not specified | Not specified | Not specified | Mean: 50.5 ± 14.4 Range: 19–80 | 55% female |
| Hamidou et al. (27) | Breast | AJCC stage: 0–4 | 283 patients had LND | Chemotherapy; hormone therapy; radiotherapy; surgery | Not specified | Not specified | Mean: 58 ± 11.1 | All female |
| Hinz et al. (28) | Prostate; kidney; bladder; testicles; penis; renal pelvis | I-IV | Not specified | Chemotherapy; hormone therapy; radiotherapy; surgery | Mean: 112.9 ± 294 | Not specified | Mean: 63.7 ± 8.3 | All male |
| Hinz (29) | Breast | Not specified | Not specified | Chemotherapy; radiotherapy; hormone therapy | At least 6 months, to over 5 years | Not specified | Mean: 66.1 ± 9.3 | All female |
| Ito et al. (30) | Rectal | TNM classification: 1–4 | TNM staging N (%): I-IIIb: 12 (92); IV: 1 (8) | Surgery | Not specified | Not specified | Mean: 66.9 ± 11.3 | 62% male |
| Jakola et al. (31) | Glioma | WHO grade II-IV | Not specified | Radiotherapy; surgery | Not specified | Not specified | Mean: 49 ± 15 | 26% female |
| Jansen et al. (32) | Breast | Early-stage | Not specified | Surgery (lumpectomy or mastectomy); radiotherapy | Not specified | Not specified | Mean: 55 ± 10 | All female |
| Jorngarden et al. (33) | CNS tumor; Ewing sarcoma; leukemia; lymphoma; osteosarcoma; other | Not specified | Not specified | Chemotherapy | Not specified | Mean: 15.7; 13–15 years (N = 35); 16–19 years (N = 21) | Not specified | 57% male |
| King-Kallimanis et al. (34) | Lung; pancreatic; esophageal; cervical | Not specified | No | Surgery | Not specified | Not specified | Mean: 57.3 ± 14.2 | 51.49% male |
| Korfage et al. (35) | Prostate | Not specified | Not specified | Active surveillance; brachytherapy; external radiotherapy; hormonal treatment; radical prostatectomy | Beginning of study | Not specified | Mean: 67.3 ± 4.4 | All male |
| Kvam et al. (14) | Multiple myeloma | Not specified | Not specified | ASCT; MP ± Thalidomide; Thalidomide; Velcade | Not specified | Not specified | Median: 66 Range: 36–89 | 54% male |
| Oort et al. (36) | Lung; pancreas; esophageal; cervical | Not specified | Not specified | Surgery | Not specified | Not specified | Mean: 57.5 ± 14.1 | 51% male |
| Ousmen et al. (37) | Breast | AJCC stage: 0–4 | 301 patients had LND | Chemotherapy; hormone therapy; radiotherapy; surgery | Not specified | Not specified | Mean: 58.4 ± 11 | All female |
| Rees et al. (38) | Prostate | TNM classification: T2–T4 | Yes, distant metastases identified in 19 patients | Active surveillance; hormone therapy; radiotherapy | Not specified | Not specified | Mean: 72.8 ± 8.5 | All male |
| Salmon et al. (39) | Breast | I-III | No | Surgery; chemotherapy; radiotherapy; hormone therapy | Not specified | Not specified | Mean: 57 ± 10.4 | All female |
| Sharpe et al. (13) | Multiple, but primarily lung and colorectal | Not specified | Yes, all patients had metastatic cancer | Chemotherapy; radiotherapy; combination; other | Metastatic cancer in previous 3 months before the study | Not specified | Mean: 64 ± 8.6 | 49% male |
| Sharpley and Christie (40) | Breast | Not specified | Not specified | Not specified | Average: 2 years 8 months | Not specified | Mean: 58.76 Range: 26–85 | All female |
| Sprangers et al. (17) | Breast; lung; prostate; Hodgkin | Not specified | Not specified | Radiotherapy | Not specified | Not specified | Median: 63 Range: 28–89 | 60% female |
| Tessier et al. (41) | Breast | TNM classification: I or II | No | Not specified | First survey distributed 1 month following diagnosis | Not specified | Mean: 53 | All female |
| Traa et al. (42) | Colorectal | Not specified | Non-curatively treated metastases at baseline excluded | Chemotherapy; radiotherapy; surgery | Not specified | Not specified | Mean: 62 ± 8.6 | 71.2% male |
| Verdam et al. (43) | Breast; prostate; lung; other | Not specified | Yes, all with bone metastases from a solid tumor | Not specified | Not specified | Not specified | Mean: 64.87 | 46% female |
| Verdam et al. (44) | Breast; colorectal; lung; other | Not specified | Yes in 40% of patients | Chemotherapy; radiotherapy | Not specified | Not specified | Mean: 57 ± 12.1 | 41% male |
| Visser et al. (45) | Head and neck; gastrointestinal; gynecological; lung; breast; genitourinary tract; hematological malignancies; other | Not specified | Not specified | Radiotherapy | Not specified | Not specified | Mean: 64 ± 13 | 58% male |
| Visser et al. (36) | Lung; periampullary; esophageal; cervical | Not specified | Not specified | Surgery | Not specified | Not specified | Mean: 57.7 ± 14.1 Range: 27–83 | 51% male |
| Visser et al. (4) | Lung; periampullary; esophageal; cervical | Not specified | Not specified | Surgery | Not specified | Not specified | Mean: 57.28 ± 14.2 | 51% male |
| von Blackenburg et al. (47) | Breast; lung; urologic; digestive; Gynecologic; other | Not specified | Yes in 29 patients (33.7%) | Chemotherapy; radiotherapy; Surgery | Not specified | Not specified | Mean: 52.5 ± 8.1 Range: 31–65 | 53.5% female |
| Westerman et al. (48) | Lung | Not specified | Not specified | Chemotherapy | Not specified | Not specified | Mean: 58.7 Range: 46–72 | 47.8% male |
AJCC, American Joint Committee on Cancer; ASCT, autologous stem cell transportation; CNS, central nervous system; LND, lymph node dissection; MP, Melphalan and Prednisone; TNM, Tumor Node Metastasis; WHO, World Health Organization.